Clinical Trial Update: Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a genetic subtype-matched targeted therapy for newly diagnosed Diffuse Large B-Cell Lymphoma with TP53 mutation; currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Status: RECRUITING